by Q1Web Admin | Feb 22, 2017 | News
At the six-week mark of its fifty-four-week study, Pfizer released data for its biosimilar, Inflectra as a treatment for Crohn’s disease. Previously, Inflectra was approved to treat moderate to severe Crohn’s disease but did not have Crohn’s-specific data. With its...
